Our Partners and Supporters
Scientific Partners
Commercial Partners
Clients
Our Affiliations
Active funding
AI-RITMIA: AI-assisted peRsonalized heart-on-chIp as advanced diagnostic Tool for clinical significance assessMent of Inherited cArdiomyopathies
Funding agency: European Commission
Funding scheme: Horizon Europe, EIC Pathfinder
“Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. Grant Agreement: 101257934.”
Inherited cardiomyopathies (iCMPs) are a major causeInherited cardiomyopathies (iCMPs) are a major cause of heart disease and account for a significant percentage of deaths in young patients. While recent advances in next-generation sequencing have enabled testing of a large number of genes related to iCMPs, the rate of identification of pathogenic variants is still below 50%. On the other hand, this unprecedented sequencing power has led to an exponential increase in detecting novel unclassified genetic variants (VUS), for which pathogenicity has not been confirmed. VUS uncertainty of diagnosis poses important problems in clinical evaluations, therapeutic decisions and risk-assessment both for patient and family members. The AI-RITMIA Consortium proposes a breakthrough innovation to establish a conclusive link between specific VUSs and CMP clinical phenotypes, yielding to the development of an unprecedented technological platform: a radically new AI-guided patient-specific heart-on-chip diagnostic tool (AI-RITMIA) will be able to interface for the first time three currently diverging sectors: patient specific in vitro modelling, in silico and artificial intelligence (AI) based data handling and clinical evaluation. AI-RITMIA will be the first clinical grade personalized in vitro-in silico platform enabling faster and unbiased correlations of clinical outcomes with functional in vitro profiling for VUS-carrying patients, returning a pathogenicity score directly to the clinicians to unlock informed diagnosis and therapeutic decisions. The achievement of such innovation will leverage on enabling technologies and resources uniquely available in the Consortium, which brings together excellences from the three interfacing worlds: 1) in vitro models based on OoC and microsensors @POLIMI, @BIOMIMX, @NMI and patient-specific iPSCs @ICH; 2) the largest EU cohort of well characterized CMP patients @COCHIN, and 3) clinical grade AI-based data handling interfaces @TUM, @ADVICE.
BATTITO: uBeAt-powered closed-loop sTandardisaTion of heart-on-chIp assays for reliable cardioTOxicity screening
Funding agency: European Commission
Funding scheme: Horizon Europe, ERC Proof of Concept
“Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. Grant Agreement: 101334870.”
Drug-induced cardiotoxicity remains a primary cause of late-stage clinical attrition. Current preclinical safety assessments are focused heavily on electrophysiology assays and animal models and shows limited predictivity for human outcomes, largely failing to detect critical cardiac liabilities. Heart-on-Chip models represent a transformative New Approach Methodology (NAM) to address this gap. However, their routine industrial adoption is severely hindered by biological variability and a lack in standardisation. Current Heart-on-Chip models undergo open-loop, fixed maturation protocols (e.g. via electro/mechanical training), resulting in high sample-to sample variability which creates baseline noise that obscures subtle toxicological signals. BATTITO aims to demonstrate the industrial feasibility of transforming our validated beating heart-on-chip (uHeart) into a self-standardising cardiac NAM. The platform relies on the proprietary uBeat technology, a breakthrough actuator patented by Politecnico di Milano (POLIMI) and licensed to BiomimX, which provides heartbeat like training to cardiac cells. Building on the findings of the ERC Starting Grant EvOoC, which demonstrated that mechanobiological closed-loop feedback enhances tissue maturation, BATTITO will engineer an automated quality loop directly linking optical contractility readouts to the uBeat actuation controller. This autonomous adaptation of the training mechanical forces using the real-time functional state of each individual microtissue will force biological convergence toward a highly standardised functional window. POLIMI will lead the complex mechatronic integration and the quantitative biological validation of standardisation metrics. Simultaneously, the industrial stakeholder BiomimX will execute market analysis, validate the workflow against industrial constraints, and draft the commercial exploitation roadmap. BATTITO will deliver an automated NAM platform for robust cardiotoxicity screening.
PHOENIX: Precision Human Organs-on-chip for Enhanced Neuro-muscular and Cardiac Studies
Funding agency: European Commission
Funding scheme: Horizon Europe, Innovative non-animal human-based tools and strategies for biomedical research, HORIZON-HLTH-2024-TOOL-05-06-two-stage
“Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. Grant Agreement: 101156638.”
PHOENIX aims to revolutionise biomedical research by developing the next generation human-based Organs-on-chips (OoC). OoC is a promising technology potentially able to outperform conventional preclinical models in providing patho-physiologically relevant setting for investigating human diseases, thus tackling the limited translational value of animal testing. OoC wide adoption is currently hampered by poor maturation of cellular models and shortage of non-destructive readout methods. PHOENIX will take current OoC platforms to the next level, overcoming such limitations by integration of core technologies already validated by the Consortium, namely Electric Recording (3dMEA), Force Sensing (3dFORCE) and Mechanical Stimulation (3dMECH). Two platforms will be developed: i) μHeart, to model functional cardiac tissues, and ii) μNMC to model neuro-muscular circuits. PHOENIX ecosystem will be completed by satellite products and qualified against specific contexts of use in clinically and industrially relevant environments. PHOENIX potential will be showcased with two genetic pathologies as demonstrators: LMNA-cardiomyopathies and Freidreich’s Ataxia, conditions in which electrical instability and mechanical impairment play important roles. For each platform, two versions will be released (Base and Pro), addressing the need of identified customer segments (research labs and Pharma/Biotech). In line with the 3Rs, PHOENIX platforms represent the ideal clinically relevant tools to test drugs and gene therapies, leading to faster/safer development processes, reducing the need for animal testing. Robust dissemination, exploitation and communication activities will address both key stakeholders (OoC players, end-users, end-beneficiaries and regulatory bodies) and society at large, fostering acceptance, adoption, economic viability and regulatory compliance. PHOENIX will last 4 years with a Consortium comprising 9 partners (Academic, SMEs and LEs) from 4 EU Countries.
MIRACLE: Multilevel inflammatory regulation in cardiometabolic disease
Funding agency: European Commission
Funding scheme: Horizon Europe, HORIZON-MSCA-2022-DN-01-01
“Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. Grant Agreement: 101119370.”
MIRACLE mission is to build and foster an innovative doctoral program designed to equip a team of young scientists with the critical scientific and technical expertise in single-cell and artificial intelligence technologies. This will enable them to uncover the intricate layers of inflammatory regulation in cardiometabolic disease..
The MIRACLE network brings together leading academic groups and non-academic parties including companies and knowledge societies. Specifically, the MIRACLE network connects the following institutions and companies:
- Amsterdam UMC, location Academic Medical Center, Netherlands
- Maastricht University, Netherlands
- University of Lille, France
- University of Eastern Finland
- University of Bonn, Germany
- BiomimX Srl, Italy
- Katholieke Universiteit Leuven, Belgium
- University of Bern, Switzerland
- AstraZeneca, Sweden
- University of California San Diego, US
- NanoString
- Science Matters
- European Atherosclerosis Society
IMPLANTEU: Innovative approaches to implantation research in health and disease
Funding agency: European Commission
Funding scheme: Horizon Europe, HORIZON-MSCA-2023-DN-01-01
“Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Executive Agency (REA). Neither the European Union nor the granting authority can be held responsible for them. Grant Agreement: 101169308.”
IMPLANTEU is an international community of researchers whose objectives are:
- To develop a molecular blueprint of human implantation in health and disease;
- To improve implantation fitness for food production mammals and
- To develop an advanced toolkit for implantation research.
IMPLANTEU provides multi-species, multi-sector and multi-model molecular and system implantation research, integrating complementary expertise in reproductive and stem cells biology, medicine, physiology, ethics and law, and cutting-edge technologies such as stem cell-based embryo models, organoids, machine learning, and organ-on-chip.
IMPLANTEU will train 13 doctoral candidates through research, innovation, secondments in academic and industrial environments, horizontal and focused courses, and interactions with stakeholders. The findings generated through IMPLANTEU will contribute to the profound understanding of the embryonic and endometrial contribution to reproductive success, innovations in infertility treatment, animal production efficiency and sustainability, tissue bioengineering, pathogen-host interaction, reproductive toxicology, and stem cell biology.
Past funding
Design Momentum ha supportato BiomimX nel rafforzamento del modello di business, del posizionamento sul mercato pharma e del design di prodotto per le proprie tecnologie organ-on-chip.
Progetto realizzato con il contributo del Programma Regionale FESR Lombardia 2021–2027 di Regione Lombardia, nell’ambito del bando “Programma di accelerazione per le PMI della moda e del design” (fesr.regione.lombardia.it)
Smart&Start
Funding agency: Invitalia
Funding scheme: Smart&Start
Brevetti+ 2022
Funding agency: Invitalia
Funding scheme: Brevetti+ 2022
Progetto finanziato con la misura Brevetti + con fondi dell’Unione europea – NextGenerationEU”
- Denominazione del soggetto ricevente: BIOMIMX SRL
- CLP: BRE: BRE0000170; CUP: C89J23000200008
- Somma incassata complessiva: € 111.071,60
- Data di incasso 06/12/2023(€ 65.503,60) e 12/11/2024 (€ 45.568)
SINERGIA: Advanced technologies for drug discovery and precision medicine: in vitro modelling human physiology and disease
Funding agency: European Commission
Funding scheme: H2020, MSCA-ITN-ETN-2019
“This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860715.”
SINERGIA is a project funded by the European Union in the framework of the H2020 Marie Skłodowska Curie Actions – Innovative Training Networks. SINERGIA aims to provide breakthrough strategies for the implementation of new in vitro preclinical platforms in terms of innovative technologies, biological models and drug screening approaches in the effort of bridging the gap between current, simplistic in vitro cultures and faithful and effective future physiological models.
SINERGIA beneficiaries consist of five universities (POLIMI, UNIBAS, UMaastricht, ICRC Brno, UKA) and five non-academic partners: 1 large enterprise (ACCELERA), 3 SMEs (LIFETEC, BIOMIMX and MTTLAB) and 1 hospital (EOC). Four partner organizations are also involved: 3 hospitals (MONZINO, EIO, IOG) and 1 SME (ST-UK).
uBeat: Mimic human complexity in a Beat to revolutionize the drug development
Funding agency: European Commission
Funding scheme: Horizon Europe, Women Tech EU
This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101071659.
uHeart: A beating Heart-on-Chip for pre-clinical early detection of drugs cardiac safety
Funding agency: European Commission
Funding scheme: H2020, SME Instrument phase 1
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 888726.
Brevetti+ 2019
Funding agency: Invitalia
Funding scheme: Brevetti+ 2019
- Denominazione del soggetto ricevente: BIOMIMX SRL
- Denominazione del soggetto erogante: INVITALIA
- Somma incassata complessiva: € 82.590,72
- Data di incasso 22/02/2021 (€ 42.236,93) e 03/03/2022 (€ 40.353,79)
- Causale: BANDO BREVETTI + 2019 -– Decreto Direttoriale del 26/11/2019 ID progetto BRE0000170